Premium
Conservative treatment of early endometrial cancer
Author(s) -
Bovicelli Alessandro,
D'Andrilli Giuseppina,
Giordano Antonio,
De Iaco Pierandrea
Publication year - 2013
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.24292
Subject(s) - endometrial cancer , progestin , medicine , female circumcision , gynecology , fertility , cancer , incidence (geometry) , carcinoma , oncology , hormone , population , environmental health , physics , optics
Abstract Endometrial cancer is the most common cancer of the female genital tract in Europe and in the United States. Endometrial cancer has increased 21% in incidence since 2008, and the death rate has increased more than 100% over the past two decades. Approximately 15% of patients with endometrial cancer are pre‐menopausal. The aim of this review is to discuss the conservative management of endometrial cancer. A number of studies largely support the conservative treatment of endometrial carcinoma (EC) in women desiring future fertility. We focus on the role of progestin hormonal therapy, including the risks associated with non‐standard care, appropriate candidate selection, expected outcomes, various progestin agents and recommended follow‐up. J. Cell. Physiol. 228: 1154–1158, 2013. © 2012 Wiley Periodicals, Inc.